CAFC Reverses Massive Jury Verdict for Juno and Sloan Kettering
IP Watchdog
AUGUST 26, 2021
The CAFC found that the jury’s verdict with respect to written description was not supported by substantial evidence. The patent generally covers cancer immunotherapy technology. The case relates to U.S. 7,446,190, owned by Sloan Kettering, which is titled “Nucleic Acids Encoding Chimeric T Cell Receptors.” Juno sued Kite Pharma, Inc.
122 
Let's personalize your content